TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7526028

Group type: EXPERIMENTAL
Intervention: Chemotherapy with ifosfamide, cisplatin, and adriamycin
Number of subjects: 94
Study: 4073304

Group type: EXPERIMENTAL
Intervention: Structured treatment (drug use exceeding set limits resulted in methadone withdrawal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unstructured treatment (no consequences attended continued drug use)
Number of subjects: 0
Study: 31980691

Group type: EXPERIMENTAL
Intervention: DASH-style diet intervention
Number of subjects: 19
Study: 29291357

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert (MVI)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (DVI)
Number of subjects: 401
Study: 27471125

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (HP) mouthwash 3%
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline (NS) mouthwash 0.9%
Number of subjects: 68
Study: 23319006

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Behavioral avoidance task
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Functional neuroimaging during classical fear conditioning
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Differentiation in brain activation patterns post-CBT
Number of subjects: 369
Study: 22071311

Group type: EXPERIMENTAL
Intervention: RT+ (irradiated group, n=30)
Number of subjects: 75

Group type: COMPARATOR
Intervention: RT- (non-irradiated group, n=45)
Number of subjects: 75
Study: 20929128

Group type: EXPERIMENTAL
Intervention: Tetramethylpyrazine (TMP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low molecular dextran (Control)
Number of subjects: 60
Study: 18620949

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa‐2b 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years
Number of subjects: 1256

Group type: COMPARATOR
Intervention: observation
Number of subjects: 1256

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa‐2b
Number of subjects: 1256
Study: 17516971

Group type: EXPERIMENTAL
Intervention: 1000 micrograms self-administered vaginal misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-administered vaginal placebo
Number of subjects: 0
Study: 15612099

Group type: COMPARATOR
Intervention: Sustained-release methylphenidate tablets (18 mg to 54 mg/day in a single dose)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Sustained-release methylphenidate capsules
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate tablets
Number of subjects: 435

Group type: COMPARATOR
Intervention: Short-acting methylphenidate
Number of subjects: 435
Study: 10871573

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (60 mg retinol equivalent)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 9181227

Group type: EXPERIMENTAL
Intervention: Physiotherapy starting on postoperative day 1
Number of subjects: 163

Group type: COMPARATOR
Intervention: Physiotherapy starting on postoperative day 7
Number of subjects: 163
Study: 1327742

Group type: EXPERIMENTAL
Intervention: 55 g low-fibre oat bran
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 55 g high-fibre oat bran
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 80 g mixed cooked beans
Number of subjects: 40

Group type: COMPARATOR
Intervention: low-fat background diet (29% of energy from fat)
Number of subjects: 40
Study: 3893961

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ranitidine 50 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg and Ranitidine 50 mg
Number of subjects: 50
Study: 31140565

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 140
Study: 24809656

Group type: EXPERIMENTAL
Intervention: Aussie current
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PC500 current
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PC200 current
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Russian current
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: NMES combined with MVC
Number of subjects: 21

Group type: COMPARATOR
Intervention: NMES
Number of subjects: 21
Study: 23948023

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VVC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pressure-controlled ventilation (VPC)
Number of subjects: 26
Study: 21813065

Group type: EXPERIMENTAL
Intervention: sCD163 at baseline (1.69mg/l (1.42‐2.10))
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: sCD163 at 9 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline levels of sCD163
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: sCD163 levels in RA patients
Number of subjects: 34
Study: 19184245

Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 38

Group type: COMPARATOR
Intervention: CT
Number of subjects: 38
Study: 17163350

Group type: EXPERIMENTAL
Intervention: Dynamic Brain Self-Reference (dynBSR)
Number of subjects: 0
Study: 12777644

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with ondansetron treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ondansetron treatment alone
Number of subjects: 39
Study: 10836193

Group type: EXPERIMENTAL
Intervention: Fostimon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metrodin HP
Number of subjects: 60
Study: 9352450

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) treatment
Number of subjects: 9
Study: 8462535

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 75

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 3884084

Group type: EXPERIMENTAL
Intervention: Melphalan 0.2 mg/kg for 5 consecutive days every 6 weeks for 2 years
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Oral combination therapy (melphalan 10 mg daily for 5 consecutive days, plus methotrexate 15 mg and 5-fluorouracil 250 mg on the first day, courses repeated every 6 weeks for 2 years)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 273
Study: 30760314

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 108

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 108

Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 108
Study: 30336306

Group type: EXPERIMENTAL
Intervention: Planning intervention where subjects selected the days and times they intended to attend the gym over the next two weeks
Number of subjects: 877

Group type: COMPARATOR
Intervention: Control group who recorded their days of exercise in the prior two weeks
Number of subjects: 877
Study: 27344833

Group type: EXPERIMENTAL
Intervention: Palmar thumb surface group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radial margin group
Number of subjects: 60
Study: 24104592

Group type: EXPERIMENTAL
Intervention: (18)F-Fluorocholine (FCH) PET/CT
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: (11)C-Acetate (ACE) PET/CT
Number of subjects: 23
Study: 22617413

Group type: EXPERIMENTAL
Intervention: Youth intervention
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Combined youth and parent intervention
Number of subjects: 615

Group type: COMPARATOR
Intervention: Intervention as usual (IAU)
Number of subjects: 615
Study: 20562595

Group type: EXPERIMENTAL
Intervention: 75 mg intravenous sotalol infusion administered over 2.5 hours
Number of subjects: 15

Group type: COMPARATOR
Intervention: 80 mg oral sotalol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 75 mg intravenous sotalol administered as a 5-hour infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 150 mg intravenous sotalol administered over 5 hours
Number of subjects: 15
Study: 17683529

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 3665

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3665
Study: 16199676

Group type: EXPERIMENTAL
Intervention: Child care training session for fathers including management of breastfeeding
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no training session for fathers)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Among women who reported difficulties with lactation
Number of subjects: 280
Study: 12370871

Group type: EXPERIMENTAL
Intervention: 6 hours of shaping training (6h/d group, n=7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 hours of shaping training (3h/d group, n=8)
Number of subjects: 15
Study: 9648994

Group type: EXPERIMENTAL
Intervention: Live Escherichia coli 014
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Live Proteus mirabilis
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Supernatant from live E. coli and P. mirabilis
Number of subjects: 17

Group type: COMPARATOR
Intervention: Supernatants from bacteria treated with formaldehyde or glutaraldehyde
Number of subjects: 17

Group type: COMPARATOR
Intervention: Other bacterial species (10 species tested)
Number of subjects: 17
Study: 8122498

Group type: EXPERIMENTAL
Intervention: Iron supplementation (66 mg daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 120
Study: 2589359

Group type: EXPERIMENTAL
Intervention: Intravenous followed by oral ciprofloxacin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Clindamycin-gentamicin combination
Number of subjects: 122
Study: 1099945

Group type: EXPERIMENTAL
Intervention: Ru-Tuss tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31753712

Group type: EXPERIMENTAL
Intervention: In-vitro activation (IVA) procedure
Number of subjects: 11
Study: 31610401

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean dietary intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 36
Study: 28577591

Group type: EXPERIMENTAL
Intervention: Factorial designs in clinical interventions
Number of subjects: 0
Study: 25255169

Group type: EXPERIMENTAL
Intervention: Right rTMS (10 sessions at 10 Hz frequency; 20 trains per session; 4.9 seconds per train and intertrain interval 30 seconds)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Left rTMS (10 sessions at 10 Hz frequency; 20 trains per session; 4.9 seconds per train and intertrain interval 30 seconds)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 22739327

Group type: EXPERIMENTAL
Intervention: Plyometric training (PLYO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study: 21535999

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone after learning
Number of subjects: 95
Study: 21067020

Group type: EXPERIMENTAL
Intervention: Over and over continuous suturing (Group-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous inverting sutures (Group-2)
Number of subjects: 100
Study: 16490643

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (1 mEq/kg)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 874
Study: 15362678

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenously before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: No glucocorticoid therapy for thirty days before surgery (Control)
Number of subjects: 30
Study: 10950012

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiologic saline (Group B)
Number of subjects: 30
Study: 9624373

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection (4 units total: 2 units in each nasal cavity for middle and inferior turbinate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 0
Study: 8172263

Group type: EXPERIMENTAL
Intervention: Diode laser photocoagulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Argon laser photocoagulation
Number of subjects: 14
Study: 3414581

Group type: EXPERIMENTAL
Intervention: 15 mg zinc/d
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 100 mg Zn/d
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All treatments (including vitamin-mineral supplement)
Number of subjects: 103
Study: 31639246

Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28922590

Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ABT-126 75 mg
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ABT-126
Number of subjects: 157
Study: 26866955

Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention with 3 individual counseling sessions
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Computer-assisted intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group receiving sexual health advice as part of regular HIV care
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 24432872

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8255

Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 8255
Study: 22146084

Group type: EXPERIMENTAL
Intervention: Iranian version of the Female Sexual Function Index (IV-FSFI)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: IV-FSFI
Number of subjects: 448
Study: 19556043

Group type: EXPERIMENTAL
Intervention: Total urine protein level of 3.5 g/d
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Urine total protein level of 3.5 g/d or greater at baseline
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Other signs and symptoms of nephrotic syndrome at baseline
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Progression of kidney disease during follow‐up
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Measures of proteinuria
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Threshold levels for nephrotic‐range proteinuria and albuminuria
Number of subjects: 1608
Study: 16783598

Group type: EXPERIMENTAL
Intervention: CT imaging from the CT Image Library (CTIL)
Number of subjects: 17308
Study: 15099879

Group type: EXPERIMENTAL
Intervention: Hysteroscopic rollerball electrocoagulation (RBE)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Uterine balloon thermal ablation (Thermachoice)
Number of subjects: 137
Study: 12397539

Group type: EXPERIMENTAL
Intervention: R-FCM (Rituximab + Fludarabine-Cyclophosphamide-Mitoxantrone); Rituximab 375 mg/m2 one day before FCM
Number of subjects: 147

Group type: COMPARATOR
Intervention: FCM (Fludarabine-Cyclophosphamide-Mitoxantrone) alone
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: R-FCM
Number of subjects: 147

Group type: COMPARATOR
Intervention: FCM
Number of subjects: 147
Study: 10211309

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (300,000 I.U. daily for 1 month)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 25
Study: 7796647

Group type: EXPERIMENTAL
Intervention: 5‐FU mixed with Isovist‐300 injected into the pelvic retroperitoneal space
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what treatment was used)
Number of subjects: 0
Study: 2196145

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 800 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 24 mg/kg (in monkeys)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 643471

Group type: EXPERIMENTAL
Intervention: Subliminal message 'masculine'
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subliminal message 'feminine'
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subliminal flash of white light
Number of subjects: 100

Group type: COMPARATOR
Intervention: No further stimulation (Control)
Number of subjects: 100
Study: 6129874

Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg/day or higher)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (12 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clemastine (2 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study: 30552590

Group type: EXPERIMENTAL
Intervention: 2% articaine
Number of subjects: 180

Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 180
Study: 28099429

Group type: EXPERIMENTAL
Intervention: Hypothermia at 33 °C for 48 hours after HIE birth
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 50
Study: 26070052

Group type: EXPERIMENTAL
Intervention: Earmuffs
Number of subjects: 31

Group type: COMPARATOR
Intervention: No earmuffs (control)
Number of subjects: 31
Study: 24410739

Group type: EXPERIMENTAL
Intervention: Extreme hypo-fractionation (7 × 6.1 Gy)
Number of subjects: 20
Study: 22922306

Group type: EXPERIMENTAL
Intervention: Resin infiltration (Icon, pre‐product; DMG, Hamburg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 22
Study: 19204365

Group type: EXPERIMENTAL
Intervention: Single-row rotator cuff repair
Number of subjects: 40

Group type: COMPARATOR
Intervention: Double-row rotator cuff repair
Number of subjects: 40
Study: 17551300

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine 60 mg/m2 (dose-escalated to 70 mg/m2 after initial 3 weeks if no unacceptable toxicity)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Intravenous vinorelbine 30 mg/m2 weekly
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine for patients with KPS 60-70
Number of subjects: 181

Group type: COMPARATOR
Intervention: Intravenous vinorelbine for patients with KPS 60-70
Number of subjects: 181
Study: 15135024

Group type: EXPERIMENTAL
Intervention: Food reinforcement
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Hedonic ratings for preferred food
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Multiple-regression models
Number of subjects: 74
Study: 12030601

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (100 microg/m2, sc)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10406818

Group type: EXPERIMENTAL
Intervention: ACE II and ID genotype individuals (n=10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: ACE DD individuals (n=8)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: apoE3 and E4 individuals (n=15)
Number of subjects: 26

Group type: COMPARATOR
Intervention: apoE2 individuals (n=3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LPL PvuII +/+ individuals (n=4)
Number of subjects: 26

Group type: COMPARATOR
Intervention: LPL PvuII +/− and −/− individuals (n=14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LPL HindIII +/+ and +/− individuals (n=15)
Number of subjects: 26

Group type: COMPARATOR
Intervention: LPL −/− individuals (n=3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: LPL PvuII −/− individuals (n=3)
Number of subjects: 26

Group type: COMPARATOR
Intervention: LPL PvuII +/− and +/+ individuals (n=15)
Number of subjects: 26
Study: 7594341

Group type: EXPERIMENTAL
Intervention: Lansoprazole (group L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine (group R)
Number of subjects: 0
Study: 2343792

Group type: EXPERIMENTAL
Intervention: Audiotaped administration of the Situational Competency Test (SCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written administration of the Situational Competency Test (SCT)
Number of subjects: 0
Study: 373450

Group type: EXPERIMENTAL
Intervention: Dipivalyl epinephrine, 0.1%
Number of subjects: 17

Group type: COMPARATOR
Intervention: Epinephrine hydrochloride, 2%
Number of subjects: 17
Study: 31337325

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as Usual (Referral to PTSD 'Standard Care')
Number of subjects: 80
Study: 27702807

Group type: EXPERIMENTAL
Intervention: 1.25% fluoride gel
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 46
Study: 24383912

Group type: COMPARATOR
Intervention: Platform Switching (PS) abutments
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Non-Platform Switching (NPS) abutments
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (PS and NPS)
Number of subjects: 19
Study: 24007599

Group type: EXPERIMENTAL
Intervention: Physical activity prescription + hyper‐corrective night‐time brace
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Physical activity prescription + postural scoliosis‐specific exercises
Number of subjects: 135

Group type: COMPARATOR
Intervention: Physical activity prescription (control group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 135
Study: 21285388

Group type: EXPERIMENTAL
Intervention: Exenatide BID (5 μg for 4 weeks, then 10 μg)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Premixed insulin aspart 70/30 BID (PIA)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 354
Study: 19002124

Group type: EXPERIMENTAL
Intervention: Early delivery of stem cells via intramyocardial injection and intracoronary infusion (3-6 weeks after AMI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Late delivery of stem cells via intramyocardial injection and intracoronary infusion (3-4 months after AMI)
Number of subjects: 60
Study: 16765113

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa blockade
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Heparin and planned GP IIb/IIIa blockade
Number of subjects: 1558
Study: 15450560

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 16505

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass
Number of subjects: 16505